

Special Issue

Machine Learning in Epidemiology

Message from the Guest Editors

Artificial intelligence (AI) and machine learning (ML) are revolutionizing epidemiology, offering unprecedented tools for analyzing vast amounts of health data and generating previously unobtainable insights. AI/ML approaches also encourage personalized healthcare by tailoring interventions based on individual risk factors and population-level trends, thus enhancing both prevention and treatment strategies. We invite submissions that explore the innovative use of AI and ML in epidemiological research, with a particularly interest in how these methodologies can be leveraged to improve disease outbreak predictions, support public health decision making, and utilize both structured and unstructured data to achieve more precise health outcomes. Additionally, we welcome research that highlights the challenges, ethical considerations, and future directions in AI/ML integration in the field of epidemiology. This Special Issue aims to contribute to the development of more effective, data-driven public health strategies essential for addressing current and emerging health challenges.

Guest Editors

Dr. Xingyu Zhang


School of Health and Rehabilitation Science, University of Pittsburgh,
Pittsburgh, PA 15260, USA

Dr. Leming Zhou

Department of Health Information Management, University of
Pittsburgh, Pittsburgh, PA 15260, USA

Deadline for manuscript submissions

30 May 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/216759

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).